Nebenwirkungen

EU-Zulassung für Semaglutid-Tablette: 17% Gewichtsverlust, aber strikte Einnahme

by

The European Medicines Agency (EMA) and regulatory bodies worldwide are closely monitoring the clinical development of oral semaglutide for weight management, a treatment that has demonstrated significant potential in clinical trials such as the OASIS program. While the injectable version of the GLP-1 receptor agonist is already established, the oral formulation requires strict adherence to … Read more

GLP-1 and Obesity Treatment: Metabolic Health, Long-Term Therapy, and Future Innovations

by

For decades, the global approach to treating obesity was framed primarily as a battle of willpower. Patients were told to “eat less and move more,” a mantra that often ignored the complex biological drivers of weight gain and the stubborn nature of metabolic adaptation. However, a pharmacological shift is currently underway, transforming obesity from a … Read more

Neurophet’s AI-Powered Alzheimer’s Diagnostic Tool Receives FDA Approval

by

: ## Analysis of the Article 1.‍ Core⁢ Topic: the⁤ article discusses the ⁤FDA approval of NeurophetS AI-powered software, “Neurophet AQUA AD Plus,” designed to assist doctors in monitoring patients undergoing⁢ treatment for Alzheimer’s disease, specifically focusing on detecting potential side effects of new medications. ⁤It also touches on the broader trend of AI integration … Read more